Cargando…

Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in “Real Life”

Etelcalcetide is a new calcimimetic indicated for the treatment of secondary hyperparathyroidism (SHPT) in dialysis patients. Etelcalcetide efficacy in SHPT has been ascertained only in randomized controlled trials. This multicenter study was carried out in “real world” setting that is different fro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Russo, Domenico, Tripepi, Rocco, Malberti, Fabio, Di Iorio, Biagio, Scognamiglio, Bernadette, Di Lullo, Luca, Paduano, Immacolata Gaia, Tripepi, Giovanni Luigi, Panuccio, Vincenzo Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678718/ https://www.ncbi.nlm.nih.gov/pubmed/31330805 http://dx.doi.org/10.3390/jcm8071066

Ejemplares similares

Correction: Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in “Real Life”. J. Clin. Med. 2019, 8, 1066
por: Russo, Domenico, et al.
Publicado: (2020)

Does Etelcalcetide reverse myelofibrotic bone changes due to hyperparathyroidism? A case report
por: Panuccio, Vincenzo Antonio, et al.
Publicado: (2023)

Paget’s Disease and Secondary Hyperparathyroidism: Is Healing Possible?
por: Panuccio, Vincenzo Antonio, et al.
Publicado: (2020)

Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide
por: Cozzolino, Mario, et al.
Publicado: (2017)

Managing hyperparathyroidism in hemodialysis: role of etelcalcetide
por: Eidman, Keith E, et al.
Publicado: (2018)

A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism
por: Yokoyama, Keitaro, et al.
Publicado: (2017)

Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients
por: Cunningham, John, et al.
Publicado: (2019)

An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism
por: Block, Geoffrey A., et al.
Publicado: (2019)

One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism
por: Bushinsky, David A, et al.
Publicado: (2019)

One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism
por: Bushinsky, David A, et al.
Publicado: (2019)

Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis
por: Wolf, Myles, et al.
Publicado: (2019)

Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis
por: Chen, P, et al.
Publicado: (2016)

Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore
por: Khan, Behram A, et al.
Publicado: (2023)

Clinical Epidemiology of Systolic and Diastolic Orthostatic Hypotension in Patients on Peritoneal Dialysis
por: Torino, Claudia, et al.
Publicado: (2021)

Pro-inflammatory cytokines and bone fractures in CKD patients. An exploratory single centre study
por: Panuccio, Vincenzo, et al.
Publicado: (2012)

Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy
por: Friedl, Claudia, et al.
Publicado: (2018)

A Prospective, Randomized Clinical Trial of Etelcalcetide in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism (the DUET Trial)
por: Itano, Yuya, et al.
Publicado: (2020)

A case of a hemodialysis patient with secondary hyperparathyroidism who was resistant to etelcalcetide treatment but not to cinacalcet hydrochloride
por: Nakamura, Hironori, et al.
Publicado: (2021)

Home Pulse Pressure Predicts Death and Cardiovascular Events in Peritoneal Dialysis Patients
por: Panuccio, Vincenzo, et al.
Publicado: (2023)

New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology
por: Bellasi, Antonio, et al.
Publicado: (2019)

Treatment of secondary hyperparathyroidism in patients on hemodialysis using a novel synthetic peptide calcimimetic, etelcalcetide: a short-term clinical study
por: Mima, Akira, et al.
Publicado: (2018)

Sleep‐Disordered Breathing and 24‐Hour Ambulatory Blood Pressure Monitoring in Renal Transplant Patients: Longitudinal Study
por: Mallamaci, Francesca, et al.
Publicado: (2020)

Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan
por: Yokoyama, Keitaro, et al.
Publicado: (2020)

Determination of Etelcalcetide Biotransformation and Hemodialysis Kinetics to Guide the Timing of Its Dosing
por: Edson, Katheryne Z., et al.
Publicado: (2016)

Influence of dialysate Ca concentrations on the therapeutic effects of etelcalcetide with concomitant drugs in patients with secondary hyperparathyroidism
por: Shigematsu, Takashi, et al.
Publicado: (2019)

Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics
por: Arenas, Maria Dolores, et al.
Publicado: (2020)

Theoretical overview of clinical and pharmacological aspects of the use of etelcalcetide in diabetic patients undergoing hemodialysis
por: Ye, Jianzhen, et al.
Publicado: (2018)

Etelcalcetide Inhibits the Progression of Left Atrial Volume Index Compared to Alfacalcidol in Hemodialysis Patients
por: Dörr, Katharina, et al.
Publicado: (2023)

Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism
por: Yu, Longchuan, et al.
Publicado: (2017)

Severe hypercalcaemia early after kidney transplantation in two patients with severe secondary hyperparathyroidism previously treated with etelcalcetide
por: Dachy, Guillaume, et al.
Publicado: (2021)

Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients: a randomized controlled trial (ETECAR-HD)
por: Dörr, Katharina, et al.
Publicado: (2019)

Ultrapure dialysis water obtained with additional ultrafilter may reduce inflammation in patients on hemodialysis
por: Di Iorio, Biagio, et al.
Publicado: (2017)

Fractional Excretion of Phosphate (FeP) Is Associated with End-Stage Renal Disease Patients with CKD 3b and 5
por: Bellasi, Antonio, et al.
Publicado: (2019)

Etelcalcetide Versus Cinacalcet in Hemodialysis Patients in the United States: A Facility Calcimimetic Approach to Assess Real-World Effectiveness
por: Karaboyas, Angelo, et al.
Publicado: (2022)

Vitamin D and methylarginines in chronic kidney disease (CKD)
por: Torino, Claudia, et al.
Publicado: (2017)

Chronic Kidney Disease: The Silent Epidemy
por: Bellasi, Antonio, et al.
Publicado: (2019)

Effect of Vitamin D Receptor Activation on the AGE/RAGE System and Myeloperoxidase in Chronic Kidney Disease Patients
por: Torino, Claudia, et al.
Publicado: (2017)

Etelcalcetide and Paricalcitol in Chronic Kidney Disease: When the Target Is Inflammation
por: D’Marco, Luis, et al.
Publicado: (2022)

Targeting COVID-19 prevention in hemodialysis facilities is associated with a drastic reduction in central venous catheter-related infections
por: Heidempergher, Marco, et al.
Publicado: (2020)

Diagnostic Workup for Disorders of Bone and Mineral Metabolism in Patients with Chronic Kidney Disease in the Era of KDIGO Guidelines
por: Morrone, Luigi Francesco, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_0i0dg4q2ic3ues8iau0pemf6ad